Guardant Health

The assay uses RT-PCR and next-generation sequencing to detect coronavirus SARS-CoV-2 nucleic acids from upper respiratory nasal specimens.

Streck said its collection tube maintains native cell-free DNA populations and provides sample integrity by reducing the release of cellular genomic DNA.

The assay provides comprehensive genomic information to oncologists from a blood draw, using targeted next-generation sequencing of circulating cell-free DNA.

Although its research test volume decreased significantly because of the COVID-19 pandemic, the company saw revenue growth across both clinical testing and development services.

The company is employing Guardant360 in a Phase III trial assessing the efficacy of the drug both in a larger population and in women who test positive for ESR1 mutations.

The companies will work together to bring Guardant360 through regulatory approval and commercialize it as a CDx for Janssen's amivantamab. 

Of the 28 companies in the index, 18 firms saw their stock prices increase, while 10 firms' share prices decreased. 

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

News items for the in vitro diagnostics industry for the week of June 8, 2020.